An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...

Money Matters: How to cope with market volatility in 2025 ...

Money Matters: How to cope with market volatility in 2025 ...

Money Matters: How to cope with market volatility in 2025 ...

The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma. The phase 2 STARLITE 2 trial (NCT05239533) is assessing the safety and efficacy ...

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment ...

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal ...

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, ...

"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along ...